{
    "clinical_study": {
        "@rank": "36990", 
        "acronym": "CRS/HIPEC", 
        "arm_group": [
            {
                "arm_group_label": "CRS with systemic chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients undergo cytoreductive surgery (CRS) alone followed by systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment.  Administration of quality of life questionnaires throughout study duration of follow-up"
            }, 
            {
                "arm_group_label": "CRS/HIPEC with systemic chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) will be administered using carboplatin for 90 minutes.  Six weeks post surgery, systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles.  Administration of quality of life questionnaires throughout study duration of follow-up"
            }
        ], 
        "brief_summary": {
            "textblock": "Community hospital based phase II (prospective randomized) study to evaluate the toxicity of\n      cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly\n      diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian\n      tube, and primary peritoneal cancer."
        }, 
        "brief_title": "Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer", 
        "completion_date": {
            "#text": "April 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stage III Ovarian Cancer", 
            "Stage IV Ovarian Cancer", 
            "Epithelial Ovarian Cancer", 
            "Fallopian Tube Cancer", 
            "Primary Peritoneal Carcinoma", 
            "Ovarian Carcinoma", 
            "Fallopian Tube Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Fallopian Tube Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary endpoints:\n\n        -  To assess the feasibility of recruitment\n\n        -  Compare complication rates between the two study arms: CRS with HIPEC and CRS alone.\n\n      Secondary endpoints:\n\n        -  To determine risk factors for morbidity and mortality\n\n        -  Assess completion rate of 6 cycles of systemic chemotherapy\n\n        -  To determine progression free survival at 24 months\n\n        -  To determine overall survival at 1, 3, and 5 years\n\n        -  Evaluate health related quality of life\n\n      Patients who meet study criteria will be randomized into one of two treatment arms to\n      undergo cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic\n      intraperitoneal chemotherapy (HIPEC) followed by IV combination chemotherapy with\n      carboplatin and paclitaxel for newly diagnosed advanced stage (stage III/IV) ovarian,\n      fallopian tube or primary peritoneal cancer.  Both study arms will receive standard adjuvant\n      IV chemotherapy with carboplatin and paclitaxel for 6 cycles.\n\n      Twenty-four patients will undergo CRS with HIPEC performed by surgical and/or gynecologic\n      oncologic surgeons at Mercy Medical Center, followed by systemic IV chemotherapy with\n      carboplatin (AUC=6) and paclitaxel (175mg/m2) for 6 cycles postoperatively.\n\n      Twenty-four patients will undergo CRS performed by surgical and gynecologic oncologic\n      surgeons at Mercy Medical Center, followed by systemic IV chemotherapy with carboplatin\n      (AUC=6) and paclitaxel (175mg/m2) for 6 cycles postoperatively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical presentation of ovarian, fallopian tube or primary peritoneal cancer\n\n          -  Stage III/IV disease\n\n          -  No prior treatment or significant surgery for the management of ovarian, fallopian\n             tube, or primary peritoneal carcinoma; History of laparoscopic procedures to obtain\n             diagnostic biopsies will be permitted in the study\n\n          -  Histological confirmation\n\n          -  Eastern Cooperative Oncology Group performance status 0-2 or Karnofsky performance\n             status \u2265 70%\n\n          -  \u22641 cm residual disease at the completion of the cytoreductive surgery (GOG criteria\n             for optimally cytoreduction)\n\n          -  Bone marrow function:\n\n               1. Absolute neutrophil count (ANC) \u22651,000/mm3\n\n               2. Platelets \u2265100,000/mm3\n\n               3. Hemoglobin \u2265 8.5 g/dL\n\n          -  Renal function:\n\n             1) Creatinine \u22641.5 times the upper limit of normal or a calculated creatinine\n             clearance \u226560ml/min\n\n          -  Hepatic function:\n\n               1. Bilirubin \u22641.5 times upper limit of normal\n\n               2. Alanine aminotransferase (ALT) \u22643 times upper limit of normal\n\n               3. Aspartate aminotransferase (AST) \u22643 times upper limit of normal\n\n          -  Blood coagulation parameters:\n\n               1. Prothrombin time (PT) with International Normalized Ratio of \u22641.5 and a partial\n                  prothrombin time (PTT) \u22641.5 times upper limit of normal\n\n               2. For patients on full dose warfarin, in range International Normalized Ratio\n                  (usually between 2 and 3) and\n\n               3. Partial prothrombin time (PTT) <1.2 times upper limit of normal\n\n               4. Candidate for administration of postoperative standard platinum-based\n                  combination systemic chemotherapy (adequate bone marrow, renal, hepatic\n                  function, and blood coagulation parameters)\n\n        Exclusion Criteria:\n\n          -  Any prior treatment modality for the diagnosis of ovarian, fallopian tube, or primary\n             peritoneal cancerPrior surgical attempt of cytoreductive surgery\n\n          -  Stage I/II disease\n\n          -  Presence of other invasive malignancies or evidence of other cancer within the past 3\n             years\n\n          -  Known active acute hepatitis and confirmed diagnosis of HIV\n\n          -  Active systemic infection that requires use of parenteral antibiotics\n\n          -  History of acute coronary syndromes (ACS), within the last 6 months, according to AHA\n             definitions\n\n          -  New York Heart Association (NYHA) Class II or higher congestive heart failure\n             according to American Heart Association (AHA) definitions\n\n          -  Canadian Cardiovascular Society (CCS) Class II or higher angina grade according to\n             AHA definitions\n\n          -  Uncontrolled hypertension defined as > 140/90 and not cleared for surgery at time of\n             consent by cardiologist\n\n          -  History of cerebral artery disease and prior stroke according to AHA definitions in\n             the last 6 months\n\n          -  Renal insufficiency with serum creatinine level \u22651.5 times the upper limit of normal\n             or calculated creatinine clearance <60 ml/min\n\n          -  Patients with concurrent severe medical problems unrelated to malignancy that will\n             preclude compliance with the study or places at an unacceptable risk for\n             participation in the study determinate by study investigators\n\n          -  Pregnant women are excluded from this study because carboplatin is category D agent\n             with the potential of teratogenic effects.  Due to potential risk for adverse events\n             in nursing infants secondary to treatment of the mother with carboplatin,\n             breastfeeding should be discontinued\n\n          -  Life expectancy of < 12 weeks"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124421", 
            "org_study_id": "MMC-2014-17"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CRS with systemic chemotherapy", 
                    "CRS/HIPEC with systemic chemotherapy"
                ], 
                "description": "Cytoreductive surgery", 
                "intervention_name": "Cytoreductive Surgery (CRS)", 
                "intervention_type": "Procedure", 
                "other_name": "CRS"
            }, 
            {
                "arm_group_label": [
                    "CRS with systemic chemotherapy", 
                    "CRS/HIPEC with systemic chemotherapy"
                ], 
                "description": "Six weeks post-surgery (CRS or CRS/HIPEC) standard systemic combination chemotherapy, carboplatin (AUC=6) with paclitaxel (175mg/m2) will be administered every 21 days for 6 cycles", 
                "intervention_name": "Systemic Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Post-operative chemotherapy", 
                    "adjuvant chemotherapy"
                ]
            }, 
            {
                "arm_group_label": [
                    "CRS with systemic chemotherapy", 
                    "CRS/HIPEC with systemic chemotherapy"
                ], 
                "description": "Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants", 
                "intervention_name": "Questionnaire", 
                "intervention_type": "Other", 
                "other_name": "FACT-O Questionnaire"
            }, 
            {
                "arm_group_label": "CRS/HIPEC with systemic chemotherapy", 
                "description": "Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6", 
                "intervention_name": "Hyperthermic intraperitoneal chemotherapy", 
                "intervention_type": "Procedure", 
                "other_name": "HIPEC"
            }, 
            {
                "arm_group_label": [
                    "CRS with systemic chemotherapy", 
                    "CRS/HIPEC with systemic chemotherapy"
                ], 
                "description": "AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "Paraplatin"
            }, 
            {
                "arm_group_label": [
                    "CRS with systemic chemotherapy", 
                    "CRS/HIPEC with systemic chemotherapy"
                ], 
                "description": "175 mg/m2 IV (in the vein) day 1.  Repeat every 21 days for 6 cycles", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ovarian cancer", 
            "Cytoreductive surgery", 
            "Hyperthermic Intraperitoneal chemotherapy", 
            "Systemic chemotherapy", 
            "Primary peritoneal carcinoma", 
            "Fallopian Tube cancer"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21202"
                }, 
                "name": "Mercy Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Teresa Diaz-Montes, M.D., M.P.H", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Armando Sardi, M.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study: Outcomes After Cytoreductive Surgery (CRS) With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer", 
        "other_outcome": {
            "description": "Determine percent of patients wtih Grade I-V adverse events according to NCI criteria, Common Terminology Criteria for AE (CTCAE).", 
            "measure": "Risk factors for morbidity and mortality", 
            "safety_issue": "Yes", 
            "time_frame": "During & at study completion"
        }, 
        "overall_contact": {
            "email": "msittig@mdmercy.com", 
            "last_name": "Michelle Sittig, RN", 
            "phone": "410-332-9294"
        }, 
        "overall_official": [
            {
                "affiliation": "Mercy Medical Center", 
                "last_name": "Teresa Diaz-Montes, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mercy Medical Center", 
                "last_name": "Armando Sardi, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare post-operative complication rates between study arms", 
            "measure": "Post-operative complication rates", 
            "safety_issue": "Yes", 
            "time_frame": "30 days post-operative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124421"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "FACT-O questionnaire to assess quality of life in both study arms", 
                "measure": "Assessment of quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 weeks post-operative, upon completion of systemic chemotherapy, and years 1, 2, 3, 4, & 5"
            }, 
            {
                "measure": "Evaluate the rate of progression free survival", 
                "safety_issue": "No", 
                "time_frame": "at 24 months"
            }, 
            {
                "measure": "Evaluate overall survival", 
                "safety_issue": "No", 
                "time_frame": "at 1, 3, and 5 years"
            }
        ], 
        "source": "Mercy Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mercy Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}